French
REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated…
Overview of attention for article published in Journal of Clinical Oncology, May 2018
Altmetric Attention Score: 13
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (84th percentile)
-
Good Attention Score compared to outputs of the same age and source (78th percentile)
Readers on
- mendeley
- 71 Mendeley